- Home
- BQ vs GTBP Comparison
BQ vs GTBP Comparison
Compare BQ & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BQ
- GTBP
- Stock Information
- Founded
- BQ 2008
- GTBP 1965
- Country
- BQ China
- GTBP United States
- Employees
- BQ N/A
- GTBP N/A
- Industry
- BQ Other Specialty Stores
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- BQ Consumer Discretionary
- GTBP Health Care
- Exchange
- BQ Nasdaq
- GTBP Nasdaq
- Market Cap
- BQ 6.0M
- GTBP 5.5M
- IPO Year
- BQ 2020
- GTBP N/A
- Fundamental
- Price
- BQ $2.20
- GTBP $2.28
- Analyst Decision
- BQ
- GTBP Strong Buy
- Analyst Count
- BQ 0
- GTBP 1
- Target Price
- BQ N/A
- GTBP $11.00
- AVG Volume (30 Days)
- BQ 11.4K
- GTBP 14.8K
- Earning Date
- BQ 04-29-2025
- GTBP 05-14-2025
- Dividend Yield
- BQ N/A
- GTBP N/A
- EPS Growth
- BQ N/A
- GTBP N/A
- EPS
- BQ N/A
- GTBP N/A
- Revenue
- BQ $81,208,354.00
- GTBP N/A
- Revenue This Year
- BQ N/A
- GTBP N/A
- Revenue Next Year
- BQ N/A
- GTBP N/A
- P/E Ratio
- BQ N/A
- GTBP N/A
- Revenue Growth
- BQ N/A
- GTBP N/A
- 52 Week Low
- BQ $1.62
- GTBP $1.72
- 52 Week High
- BQ $7.40
- GTBP $10.66
- Technical
- Relative Strength Index (RSI)
- BQ 53.53
- GTBP 48.56
- Support Level
- BQ $1.79
- GTBP $2.15
- Resistance Level
- BQ $2.23
- GTBP $2.38
- Average True Range (ATR)
- BQ 0.20
- GTBP 0.17
- MACD
- BQ 0.06
- GTBP -0.01
- Stochastic Oscillator
- BQ 68.95
- GTBP 32.35
About BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.